Evidence map›Paper›PMID 32673741›Full record

Observational studyJournal of hepatology2020

The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.

Jonel Trebicka, Javier Fernandez, Maria Papp, Paolo Caraceni, Wim Laleman, Carmine Gambino, Ilaria Giovo, Frank Erhard Uschner, Cesar Jimenez, Rajeshwar Mookerjee and 61 more

2 registry-linked trialsOpen access · goldAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 235 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
235citing papers in PubMed, 3 pooled it
35.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03056612 completednot on this map

Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study

TypeobservationalSponsorJonel TrebickaRan2017 to 2018Enrolled1,314ConditionsLiver Cirrhosis With Acute DecompensationArmsObservation protocol
NCT07438288 recruitingnot on this mapstarted 2022, after this paper: background citation

Predictors of Decompensation, Acute-on-chronic Liver Failure and Mortality in Liver Cirrhosis - a Multicentre, Prospective, Observational Study From the SingHealth Chronic Liver Disease Registry (SoLiDaRity-DAM)

Typeobservational_patient_registrySponsorSingapore General HospitalRan2022 to 2032Enrolled2,200ConditionsCirrhosis and Chronic Liver DiseaseArmsObservation
3 · Its place in the literature

Who cites it

235 citing papers in PubMed, 3 syntheses or guidelines pooled it, 483 citations in OpenAlex.

  1. Albumin for people with liver cirrhosis and bacterial infections.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. [Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Machine learning-derived clinical phenotypes of ascites in cirrhosis: A multi-center latent class analysis with external validation.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

175 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

71 authors at 20 institutions in 14 countries.

Jonel TrebickaEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain; JW Goethe University Hospital, Frankfurt, Germany. Electronic address: jonel.trebicka@kgu.de.
Javier FernandezEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain; Hospital Clinic, IDIBAPS and CIBEehd, Barcelona, Spain.
Maria PappUniversity of Debrecen, Faculty of Medicine, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary.
Paolo CaraceniUniversity of Bologna, Bologna, Italy.
Wim LalemanUniversity of Leuven, Leuven, Belgium.
Carmine GambinoDepartment of Medicine, University of Padova, Padova, Italy.
Ilaria GiovoDivision of Gastroenterology and Hepatology, Città della Salute e della Scienza Hospital, University of Torino, Torino, Italy.
Frank Erhard UschnerJW Goethe University Hospital, Frankfurt, Germany.
Cesar JimenezLiver Unit, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, CIBEREHD, Barcelona, Spain.
Rajeshwar MookerjeeUCL Medical School, Royal Free Hospital, London, United Kingdom.
Thierry GustotUniversite Libre de Bruxelles, Bruxelles, Belgium.
Agustin AlbillosDepartment of Gastroenterology, Hospital Universitario Ramón y Cajal, IRYCIS, University of Alcalá, CIBEREHD, Madrid, Spain.
Rafael BañaresGastroenterology and Hepatology Department, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, CIBERehd, Madrid, Spain.
Martin JanickoPavol Jozef Safarik University in Kosice, Kosice, Slovakia.
Christian SteibDepartment of Medicine II, University Hospital Munich, Munich, Germany.
Thomas ReibergerMedical University of Vienna, Vienna, Austria.
Juan AcevedoUniversity Hospitals Plymouth NHS Trust, Plymouth, UK.
Pietro GattiInternal Medicine PO Ostuni, ASL Brindisi, Italy.
William BernalKing's College Hospital, London, United Kingdom.
Stefan ZeuzemJW Goethe University Hospital, Frankfurt, Germany.
Alexander ZipprichUniversity Hospital Halle-Wittenberg, Halle (Saale), Germany.
Salvatore PianoDepartment of Medicine, University of Padova, Padova, Italy.
Thomas BergDivision of Hepatology, Department of Medicine II, Leipzig University, Medical Center, Leipzig, Germany.
Tony BrunsJena University Hospital, Jena, Germany; Aachen University Hospital, Aachen, Germany.
Flemming BendtsenHvidovre University Hospital, Hvidovre, Denmark.
Minneke CoenraadLeiden University Medical Center, Leiden, Netherlands.
Manuela MerliDepartment of Translational and Precision Medicine, Universitá Sapienza Roma, Roma, Italy.
Rudolf StauberMedical University of Graz, Graz, Austria.
Heinz ZollerMedical University of Innsbruck, Innsbruck, Austria.
José Presa RamosCHTMAD Vila Real, Vila Real, Portugal.
Cristina SolèHospital Clinic, IDIBAPS and CIBEehd, Barcelona, Spain.
Germán SorianoHospital de la Santa Creu i Sant Pau and CIBERehd, Barcelona, Spain.
Andrea de GottardiUniversity Clinic of Visceral Surgery and Medicine-Inselspital, Bern and Ente Ospedaliero Cantonale, Universita della Svizzera Italiana, Lugano, Switzerland.
Henning GronbaekAarhus University Hospital, Aarhus, Denmark.
Faouzi SalibaAP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Universite Paris Saclay, INSERM Unit 1193, Villejuif, France.
Christian TrautweinAachen University Hospital, Aachen, Germany.
Osman Cavit ÖzdoganMarmara University, Istanbul, Turkey.
Sven FrancqueUniversity Hospital Antwerp, Antwerpen, Belgium.
Stephen RyderNIHR Biomedical Research Centre at Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom.
Pierre NahonAP-HP, Hôpital Jean Verdier, Service d'Hépatologie, Bondy; Université Paris 13, Sorbonne Paris Cité, "Equipe labellisée Ligue Contre le Cancer", Saint-Denis; Inserm, UMR-1162, "Génomique fonctionnelle des tumeurs solides", Paris, France.
Manuel Romero-GomezVirgen del Rocío University Hospital, Sevilla, Spain.
Hans Van VlierbergheGhent University Hospital, Ghent, Belgium.
Claire FrancozAPHP, Hôpital Beaujon, Service d'Hépatologie, Clichy, France; Inserm, Université de Paris, Centre de Recherche sur L´Inflammation, Paris, France.
Michael MannsHannover Medical School, Hannover, Germany.
Elisabet GarciaEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain.
Manuel TufoniUniversity of Bologna, Bologna, Italy.
Alex AmorosEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain.
Marco PavesiEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain.
Cristina SanchezEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain.
Anna CurtoEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain.
Carla PitarchEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain.
Antonella PutignanoUniversite Libre de Bruxelles, Bruxelles, Belgium.
Esau MorenoEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain.
Debbie ShawcrossKing's College Hospital, London, United Kingdom.
Ferran AguilarEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain.
Joan ClàriaEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain; Hospital Clinic, IDIBAPS and CIBEehd, Barcelona, Spain.
Paola PonzoDivision of Gastroenterology and Hepatology, Città della Salute e della Scienza Hospital, University of Torino, Torino, Italy.
Christian JansenUniversity Hospital Bonn, Bonn, Germany.
Zsuzsanna VitalisUniversity of Debrecen, Faculty of Medicine, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary.
Giacomo ZaccheriniUniversity of Bologna, Bologna, Italy.
Boglarka BaloghUniversity of Debrecen, Faculty of Medicine, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary.
Victor VargasLiver Unit, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, CIBEREHD, Barcelona, Spain.
Sara MontagneseDepartment of Medicine, University of Padova, Padova, Italy.
Carlo AlessandriaDivision of Gastroenterology and Hepatology, Città della Salute e della Scienza Hospital, University of Torino, Torino, Italy.
Mauro BernardiUniversity of Bologna, Bologna, Italy.
Pere GinèsHospital Clinic, IDIBAPS and CIBEehd, Barcelona, Spain.
Rajiv JalanEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain; UCL Medical School, Royal Free Hospital, London, United Kingdom.
Richard MoreauEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain; APHP, Hôpital Beaujon, Service d'Hépatologie, Clichy, France; Inserm, Université de Paris, Centre de Recherche sur L´Inflammation, Paris, France.
Paolo AngeliEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain; Department of Medicine, University of Padova, Padova, Italy.
Vicente ArroyoEuropean Foundation for Study of Chronic Liver Failure, EF-Clif, Barcelona, Spain.
PREDICT STUDY group of the EASL-CLIF Consortium
European Foundation for the Study of Chronic Liver Failure · ESUniversity of Padua · ITUniversity of Bologna · ITConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversity of Debrecen · HUUniversity of Pavol Jozef Šafárik · SKHospital Clínic de Barcelona · ESKing's College Hospital · GBMedizinische Hochschule Hannover · DEUniversitätsklinikum Aachen · DEUniversité Libre de Bruxelles · BEUniversity College London · GBAarhus University Hospital · DKAntwerp University Hospital · BEAssociation for the Development of Douro Viticulture · PTCentre de Recherche sur l'Inflammation · FRCentro de Investigación Biomédica en Red · ESEnte Ospedaliero Cantonale · CHGhent University Hospital · BEGoethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsAcute decompensation (AD) of cirrhosis is defined as the acute development of ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof, requiring hospitalization. The presence of organ failure(s) in patients with AD defines acute-on-chronic liver failure (ACLF). The PREDICT study is a European, prospective, observational study, designed to characterize the clinical course of AD and to identify predictors of ACLF.

methodsA total of 1,071 patients with AD were enrolled. We collected detailed pre-specified information on the 3-month period prior to enrollment, and clinical and laboratory data at enrollment. Patients were then closely followed up for 3 months. Outcomes (liver transplantation and death) at 1 year were also recorded.

resultsThree groups of patients were identified. Pre-ACLF patients (n = 218) developed ACLF and had 3-month and 1-year mortality rates of 53.7% and 67.4%, respectively. Unstable decompensated cirrhosis (UDC) patients (n = 233) required ≥1 readmission but did not develop ACLF and had mortality rates of 21.0% and 35.6%, respectively. Stable decompensated cirrhosis (SDC) patients (n = 620) were not readmitted, did not develop ACLF and had a 1-year mortality rate of only 9.5%. The 3 groups differed significantly regarding the grade and course of systemic inflammation (high-grade at enrollment with aggravation during follow-up in pre-ACLF; low-grade at enrollment with subsequent steady-course in UDC; and low-grade at enrollment with subsequent improvement in SDC) and the prevalence of surrogates of severe portal hypertension throughout the study (high in UDC vs. low in pre-ACLF and SDC).

conclusionsAcute decompensation without ACLF is a heterogeneous condition with 3 different clinical courses and 2 major pathophysiological mechanisms: systemic inflammation and portal hypertension. Predicting the development of ACLF remains a major future challenge. CLINICALTRIALS. GOV NUMBER: NCT03056612. LAY SUMMARY: Herein, we describe, for the first time, 3 different clinical courses of acute decompensation (AD) of cirrhosis after hospital admission. The first clinical course includes patients who develop acute-on-chronic liver failure (ACLF) and have a high short-term risk of death - termed pre-ACLF. The second clinical course (unstable decompensated cirrhosis) includes patients requiring frequent hospitalizations unrelated to ACLF and is associated with a lower mortality risk than pre-ACLF. Finally, the third clinical course (stable decompensated cirrhosis), includes two-thirds of all patients admitted to hospital with AD - patients in this group rarely require hospital admission and have a much lower 1-year mortality risk.

Indexed as

Acute-On-Chronic Liver FailureEuropeFemaleFollow-Up StudiesHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedPrognosisProspective StudiesSeverity of Illness IndexSurvival RateAcute complicationsChronic liver diseaseNon-elective admissionOutcomeRisk factors

Identifiers

PMID32673741
OpenAlexW3043538464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.